{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:13:05Z","timestamp":1760044385152},"reference-count":59,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.clinthera.2016.05.007","type":"journal-article","created":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T14:04:06Z","timestamp":1464962646000},"page":"1710-1725","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective"],"prefix":"10.1016","volume":"38","author":[{"given":"Lee J.","family":"Smolen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James C.","family":"Gahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghaith","family":"Mitri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki","family":"Shiozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2016.05.007_bib1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","article-title":"Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study","volume":"74","author":"Kuo","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2016.05.007_bib2","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1093\/rheumatology\/kep086","article-title":"New insights into the epidemiology of gout","volume":"48","author":"Doherty","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2016.05.007_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II","volume":"58","author":"Lawrence","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.05.007_bib4","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.05.007_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2013.04.003","article-title":"A revised estimate of the burden of illness of gout","volume":"75","author":"Wertheimer","year":"2013","journal-title":"Curr Ther Res Clin Exp"},{"issue":"Suppl 5","key":"10.1016\/j.clinthera.2016.05.007_bib6","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.3949\/ccjm.75.Suppl_5.S13","article-title":"The role of hyperuricemia and gout in kidney and cardiovascular disease","volume":"75","author":"Edwards","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.clinthera.2016.05.007_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","article-title":"Pathogenesis of gout","volume":"143","author":"Choi","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2016.05.007_bib8","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.clinthera.2016.05.007_bib9","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1742-1241.2009.02188.x","article-title":"Update on gout and hyperuricemia","volume":"64","author":"Baker","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clinthera.2016.05.007_bib10","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1161\/01.HYP.0000069700.62727.C5","article-title":"Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?","volume":"41","author":"Johnson","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2016.05.007_bib11","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/MNH.0b013e328330d9d0","article-title":"Uric acid: a novel mediator and marker of risk in chronic kidney disease?","volume":"18","author":"Feig","year":"2009","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.clinthera.2016.05.007_bib12","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3109\/0886022X.2011.653753","article-title":"New insights into uric acid effects on the progression and prognosis of chronic kidney disease","volume":"34","author":"Filiopoulos","year":"2012","journal-title":"Ren Fail"},{"key":"10.1016\/j.clinthera.2016.05.007_bib13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1471-2369-15-122","article-title":"Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies","volume":"15","author":"Li","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.clinthera.2016.05.007_bib14","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s11596-014-1302-4","article-title":"Effect of uric-acid-lowering therapy on progression of chronic kidney disease: a meta-analysis","volume":"34","author":"Zhang","year":"2014","journal-title":"J Huazhong Univ Sci Technol Med Sci"},{"key":"10.1016\/j.clinthera.2016.05.007_bib15","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1053\/j.ajkd.2014.11.016","article-title":"Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial","volume":"65","author":"Goicoechea","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2016.05.007_bib16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/BOR.0b013e3282f54d03","article-title":"We can make gout management more successful now","volume":"20","author":"Becker","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clinthera.2016.05.007_bib17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/0003-4819-64-2-229","article-title":"Allopurinol in the treatment of gout","volume":"64","author":"Rundles","year":"1966","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2016.05.007_bib18","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/art.1780080456","article-title":"The effect of allopurinol in primary and secondary gout","volume":"8","author":"Y\u00fc","year":"1965","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.05.007_bib19","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jbspin.2011.05.010","article-title":"Treatment adherence in patients with gout","volume":"78","author":"Reach","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.clinthera.2016.05.007_bib20","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/kes431","article-title":"Rates of adherence and persistence with allopurinol therapy among gout patients in Israel","volume":"52","author":"Zandman-Goddard","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2016.05.007_bib21","unstructured":"Watson Laboratories Inc. Allopurinol [Package Insert]. Corona, CA; 2006. http:\/\/pi.watson.com\/data_stream.asp?product_group=1197&p=pi&language=E. Accessed May 10, 2013."},{"key":"10.1016\/j.clinthera.2016.05.007_bib22","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinthera.2016.05.007_bib23","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.05.007_bib24","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clinthera.2016.05.007_bib25","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.05.007_bib26","unstructured":"U.S. Census Bureau. Current population survey, annual social and economic supplement. 2010. http:\/\/www.census.gov\/population\/age\/data\/2010comp.html. Accessed October 30, 2013."},{"key":"10.1016\/j.clinthera.2016.05.007_bib27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/ard.2004.024091","article-title":"Gout epidemiology: results from the UK General Practice Research Database, 1990-1999","volume":"64","author":"Mikuls","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2016.05.007_bib28","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1001\/jama.2014.14484","article-title":"Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England","volume":"312","author":"Kuo","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2016.05.007_bib29","unstructured":"US Food and Drug Administration. Press Announcements - FDA Approves Drug for Gout Management. US Food and Drug Administration News & Events. 2009. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm149534.htm. Accessed March 30, 2014."},{"key":"10.1016\/j.clinthera.2016.05.007_bib30","unstructured":"Takeda Pharmaceuticals America, Inc. Uloric (febuxostat) [Package Insert]. Deerfield, IL; 2009."},{"key":"10.1016\/j.clinthera.2016.05.007_bib31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2016.05.007_bib32","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1525-139X.2007.00270.x","article-title":"Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events","volume":"20","author":"Dalbeth","year":"2007","journal-title":"Semin Dial"},{"key":"10.1016\/j.clinthera.2016.05.007_bib33","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/bcp.12126","article-title":"Understanding the dose-response relationship of allopurinol: predicting the optimal dosage","volume":"76","author":"Graham","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2016.05.007_bib34","unstructured":"Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey 2007-2008. 2009. http:\/\/wwwn.cdc.gov\/nchs\/nhanes\/search\/nhanes07_08.aspx. Accessed February 17, 2014."},{"key":"10.1016\/j.clinthera.2016.05.007_bib35","unstructured":"Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey 2009-2010. 2011. Available at: http:\/\/wwwn.cdc.gov\/nchs\/nhanes\/search\/nhanes09_10.aspx. Accessed February 17, 2014."},{"key":"10.1016\/j.clinthera.2016.05.007_bib36","unstructured":"Centers for Disease Control and Prevention. Incidence of diagnosed diabetes per 1,000 population aged 18-79 years, 1980-2011. Diabetes Public Health Resource. 2012. http:\/\/www.cdc.gov\/diabetes\/statistics\/incidence\/fig3.htm. Accessed February 16, 2014."},{"key":"10.1016\/j.clinthera.2016.05.007_bib37","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2016.05.007_bib38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3109\/03009742.2010.507218","article-title":"Hyperuricaemia and accelerated reduction in renal function","volume":"40","author":"Kuo","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.clinthera.2016.05.007_bib39","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3899\/jrheum.080487","article-title":"Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?","volume":"36","author":"Wu","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2016.05.007_bib40","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.2337\/dc09-0288","article-title":"Association between serum uric acid and development of type 2 diabetes","volume":"32","author":"Kodama","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2016.05.007_bib41","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3899\/jrheum.121061","article-title":"Serum urate and incidence of kidney disease among veterans with gout","volume":"40","author":"Krishnan","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2016.05.007_bib42","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.clinthera.2016.05.007_bib43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10198-014-0617-1","article-title":"Pearson IV. Cost-effectiveness of febuxostat in chronic gout","volume":"15","author":"Beard","year":"2014","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.clinthera.2016.05.007_bib44","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/15257770802136032","article-title":"Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy","volume":"27","author":"Becker","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2016.05.007_bib45","first-page":"S672","article-title":"The incidence of allopurinol hypersensitivity syndrome: a population perspective (abstract 1362)","volume":"58","author":"Khanna","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.05.007_bib46","doi-asserted-by":"crossref","first-page":"A261","DOI":"10.1016\/S1098-3015(10)70824-X","article-title":"PMS22 Economic impact of allopurinol hypersensitivity syndrome","volume":"11","author":"D\u2019Souza","year":"2008","journal-title":"Value Health"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2016.05.007_bib47","first-page":"S62","article-title":"Abstract 143 - Proposed gout treatment guidelines and meeting serum urate and flare goals","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.05.007_bib48","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/1471-2458-9-400","article-title":"16-year excess all-cause mortality of newly diagnosed type 2 diabetic patients: a cohort study","volume":"9","author":"Hansen","year":"2009","journal-title":"BMC Public Health"},{"key":"10.1016\/j.clinthera.2016.05.007_bib49","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.05.007_bib50","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1185\/03007995.2011.563284","article-title":"A new perspective on the pharmacoeconomics of colchicine","volume":"27","author":"Wertheimer","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2016.05.007_bib51","unstructured":"American Medical Association. AMA CodeManager: CPT Code\/Relative Value Search. https:\/\/ocm.ama-assn.org\/OCM\/CPTRelativeValueSearch.do. Accessed October 21, 2013."},{"key":"10.1016\/j.clinthera.2016.05.007_bib52","unstructured":"Avalere Health LLC. Trendwatch 2013 chartbook: trends affecting hospitals and health systems. 2013. http:\/\/www.aha.org\/research\/reports\/index.shtml."},{"key":"10.1016\/j.clinthera.2016.05.007_bib53","unstructured":"Walk-In Lab. Uric acid serum test. Kidney Tests. http:\/\/www.walkinlab.com\/kidney-tests\/uricacidserumtest.html. Accessed February 21, 2014."},{"key":"10.1016\/j.clinthera.2016.05.007_bib54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/RHU.0b013e3181945d2c","article-title":"The effect of serum urate on gout flares and their associated costs: an administrative claims analysis","volume":"15","author":"Halpern","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2016.05.007_bib55","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.ajkd.2009.11.017","article-title":"A health policy model of CKD 2: The cost-effectiveness of microalbuminuria screening","volume":"55","author":"Hoerger","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2016.05.007_bib56","unstructured":"US Renal Data System. USRDS 2011 annual data report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Chapter 11. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2011. http:\/\/www.usrds.org\/atlas11.aspx. Accessed March 30, 2014."},{"key":"10.1016\/j.clinthera.2016.05.007_bib57","unstructured":"Bureau of Labor Statistics. Consumer Price Index\u2013all urban consumers. Medical Care. http:\/\/data.bls.gov\/cgi-bin\/surveymost?cu. Accessed December 22, 2014."},{"key":"10.1016\/j.clinthera.2016.05.007_bib58","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","article-title":"Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study","volume":"72","author":"Rees","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2016.05.007_bib59","doi-asserted-by":"crossref","first-page":"e003627","DOI":"10.1136\/bmjopen-2013-003627","article-title":"Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study","volume":"4","author":"Goldfien","year":"2014","journal-title":"BMJ Open"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816303411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816303411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T07:55:49Z","timestamp":1536652549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816303411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0149291816303411"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.05.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}